The New Science of Human Longevity

There is a version of the longevity story that is easy to tell and mostly wrong. In it, ageing is a disease, the cure is around the corner, and the only thing standing between you and an extra fifty years is the right supplement, protocol, or investment. That version sells a great deal and explains very little.

There is another version, less dramatic and far more interesting. In it, ageing is a set of biological processes that can, for the first time, be measured with some precision; a handful of interventions have been shown to slow those processes in animals; the human evidence is thin but growing; and the credible near-term goal is not immortality but something more valuable — more years of health.

This is that version.

From description to mechanism

For most of the history of medicine, ageing was a backdrop: the thing that happened while diseases were being treated. The shift of the past two decades has been to treat it as a subject in its own right. A widely used framework, first published in 2013 and expanded since, identifies a set of interlinked biological "hallmarks" — processes such as the accumulation of damaged cells, the loss of the ability to sense nutrients, the erosion of the protective ends of chromosomes, and changes in how genes are regulated.

The importance of the framework is not that it is complete. It is that it turns ageing from a mystery into a list of targets.

The clock problem

The field's most influential tool is the biological clock: a molecular measurement that estimates how old a body is, as opposed to how old it has been. The best-known clocks read patterns of chemical marks on DNA, and their initial results were startling: they track chronological age closely, and deviations from it correlate with health outcomes.

The most important word in longevity science is not "reverse". It is "measure".

Clocks are also the field's most over-sold instrument. A clock that correlates with age is not the same as a clock that measures the thing that matters, and it is not established that moving the clock moves the outcome. Many commercial tests promise more than the science supports. The serious work now is on validating clocks against real health endpoints, and on building ones that predict rather than merely describe.

What the animal evidence says

In laboratory animals, several interventions reliably extend lifespan and healthspan. Restricting calories is the oldest and most robust. Certain drugs that act on nutrient-sensing pathways extend lifespan in mice. Clearing out damaged, non-dividing cells improves function in old animals. Reprogramming cells partway toward an embryonic state has produced striking results in specific tissues.

These findings are real and repeatable. They are also in mice. The history of medicine is a long lesson in how often something that works in mice fails in people, and the field's credibility depends on saying so plainly.

What the human evidence says

Less than you would think from the headlines. There are observational studies, a few small trials, and a great many extrapolations. Nothing has yet been shown in a rigorous human trial to slow ageing itself, as opposed to treating a specific disease of ageing. The trials that would establish this are expensive, slow, and complicated by a simple fact: ageing is not a recognised medical indication, so there is no agreed way to test a treatment for it.

That last point is quietly one of the most important in the field. Whether regulators will accept ageing biomarkers as trial endpoints will determine how fast credible evidence can accumulate.

The realistic promise

Strip away the hype and something remarkable remains. Nearly every major chronic disease — cardiovascular disease, most cancers, dementia, diabetes — shares ageing as its largest single risk factor. An intervention that slowed the underlying process even modestly would delay all of them at once. The value of that, in human terms, is difficult to overstate.

That is why this field deserves careful, sustained attention rather than either dismissal or credulity. The science is young, the incentives to overclaim are enormous, and the stakes are as high as any in medicine.

Neurazine's rule for covering it is simple. We will report the evidence with its strength attached, we will name what is unknown, and we will never tell you what to take. That is a conversation for you and a clinician. Our job is to make sure you walk into it informed.